Momcozy Showcases Latest Innovations at ABC Kids Expo 2025
Featuring Its Most Advanced Wearable Breast Pump and All-New Abdomen Solutions
Las Vegas, Nevada--(Newsfile Corp. - May 22, 2025) - Momcozy, a leading global brand in maternity and baby care, is proud to present its newest innovations at ABC Kids Expo 2025, taking place May 21-23 at Las Vegas. At Booth #110, Momcozy is showcasing a broad range of new products alongside fan favorites at this influential trade event.
Momcozy Showcases Latest Innovations at ABC Kids Expo 2025
First Offline Debut: Momcozy's Thinnest Wearable Breast Pump
Making its first in-person appearance since launching in March, the Momcozy Air 1 Ultra-Slim Breast Pump is the thinnest wearable breast pump on the market[1], measuring just 2.4 inches thick-nearly 22% thinner than Momcozy's Mobile Flow™. Its ultra-slim design and whisper-quiet motor combine to deliver an unprecedented level of discreet pumping experience.
Air 1 also features the industry's 1st transparent top-view design, allowing for easier alignment and milk volume monitoring. Its storage case doubles as a wireless charging station and, together with the pump, provides power for up to 15 sessions per charge.
"From Air 1, to Mobile Flow™ and Mobile Style™ , we continue to empower mothers to pump confidently anywhere through human-centered innovation," said Alan Cawley, senior sales director at Momcozy.
Introducing: The All-New Abdomen Solution
Momcozy also highlights its newly launched Ergowrap Postpartum Belly Band, complementing the brand's Ergonest Maternity Belly Band to offer a comprehensive abdomen solution for mothers. Engineered with the patented Ergonest Support Structure™, these bands help alleviate lower back pain, and provide comfortable support for daily activities, standing, and exercise.
Also on display is the CoolFit Nursing Bra Collection, released just last week. Designed for moms prone to overheating and sweating, the bras feature advanced Jelly Strip and seamless composite technology that adapt comfortably to changing breast shapes during pregnancy and breastfeeding.
A New Lineup of Smart Babycare Essentials
Momcozy introduces a variety of new babycare products, including:
Upgraded 2-in-1 Electric Nasal Aspirator: Equipped with powerful 65KPa hospital-grade suction and smart protection for effective nasal relief.
5-Inch Dual-Mode Smart Baby Monitor (BM04): Offers both Wi-Fi and non-Wi-Fi connectivity for flexible monitoring, safety alerts, and live sharing with up to 20 family members.
The brand is also showcasing popular products such as the ChangeGo Baby Stroller, a versatile stroller system that easily converts from a single to a double stroller, and even into a wagon. It supports 23 configurations with a variety of accessories, designed to grow with children from birth to age six.
Momcozy is rapidly expanding across retail, e-commerce, and medical channels worldwide. In the U.S., partnerships with Durable Medical Equipment (DME) providers allows eligible customers to access essentials like breast pumps through insurance, reinforcing the brand's commitment to innovation and accessibility.
Following the expo, all showcased products will be donated to Delivering Good, a nonprofit supporting at-risk children, families, and individuals. It's one more way Momcozy puts its values into action: making trusted maternity and baby care more accessible to families everywhere.
###
About Momcozy
Momcozy is a global mother and baby brand, serving over 3.6 million mothers in more than 60 countries and regions. Since 2018, we've evolved to meet the unique needs of moms and their families, offering a range of products from pregnancy through early motherhood, including wearable breast pumps, feeding gear, nursing bras, baby carriers, and more. As the Cozy Reformer, we always put moms first, delivering innovative solutions, comfort, and support to bring joy and ease to their journeys. Visit https://momcozy.com/ to learn more.
Media Contact: Phoebe xiaopr@momcozy.com
[1] Based on internal comparison of product thickness to the top 5 best-selling electric breast pumps on Amazon in the U.S., U.K., Germany, and France from Q1-Q3 2024.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253072
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Fairchild Gold Announces Closing of the Second Tranche of Its Previously Announced Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2025) - Fairchild Gold Corp. (TSXV: FAIR) ("Fairchild" or the "Company") is pleased to announce the closing of the second tranche of its non-brokered private placement for gross proceeds of $655,000.08 (the "Offering") on June 6, 2025. In connection with the closing of the Offering, the Company issued 10,916,668 units (the "Units") at a price of $0.06 per Unit. The Company previously closed a first tranche of the Offering on April 22, 2025, for gross proceeds of $810,000, and announced the upsizing of its Offering on May 28, 2025. Each Unit is comprised of one common share (a "Common Share") in the capital of the Company and one common share purchase warrant (a "Warrant"), whereby each whole Warrant shall be convertible into an additional Common Share at an exercise price of $0.15 for a period of sixty (60) months from the date of issuance. The Warrants include an acceleration clause to the effect that if the daily volume weighted average closing price of the common shares on the TSX Venture Exchange is at least $0.50 per Common Share for a period of five (5) consecutive trading days, 12 months after the closing date of the Offering (the "Triggering Event"), the Company may, within 5 days of the Triggering Event, accelerate the expiry date of the Warrants by giving notice thereof to the holders of the Warrants, by way of news release, and in such case the Warrants will expire on the first day that is 10 calendar days after the date on which such notice is given by the Company announcing the Triggering Event. The Offering constitutes a "related party transaction" under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"), as Robert Rosner, a director of the Company, participated in the Offering. Pursuant to MI 61-101, the Company will file a material change report providing disclosure in relation to each "related party transaction" on SEDAR+ under the Company's issuer profile at The Company did not file the material change report more than 21 days before the expected closing date of the Offering as the details of the Offering were not settled until shortly prior to the conclusion of the Offering, and the Company wished to complete the Offering on an expedited basis for sound business reasons. The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101. The Company is exempt from the formal valuation requirement in section 5.4 of MI 61-101 in reliance on sections 5.5(a) and (b) of MI 61-101 as the fair market value of the transaction, insofar as it involves each of the significant shareholders, is not more than 25% of the Company's market capitalization. Additionally, the Company is exempt from minority shareholder approval requirement in section 5.6 of MI 61-101 in reliance on section 5.7(1)(a) as the fair market value of the transaction, insofar as it involves each of the significant shareholders, is not more than 25% of the Company's market capitalization. The Offering was previously approved by the board of directors of the Company, including disinterested directors. No special committee was established in connection with the transaction, and no materially contrary view was expressed or made by any director. No finder's fee was paid in this Offering. The Common Shares and Warrants issued under the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance or longer for certain subscribers. The Offering remains subject to final approval of the TSX Venture Exchange. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. Fairchild intends to use the net proceeds of the Offering for geophysical surveys and expanded field work at the Company's Project in Nevada, as well as marketing and general working capital purposes. About Fairchild Gold Corp. Fairchild Gold Corp. is a mineral exploration company focused on acquiring, exploring, and developing high-quality mineral properties in mining-friendly jurisdictions. The Company's flagship Nevada Titan Project is in the historic Goodsprings mining district in Nevada, USA. The Company is also the 100% owner of the Fairchild Lake Property consisting of 108 mining claims covering an area of 2,224 hectares, located approximately 250 kilometres northwest of the city of Thunder Bay in the Patricia Mining Division, Ontario. On behalf of the Board of Directors Luis MartinsDirector and Chief Executive OfficerFairchild Gold Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this news release. Cautionary Statement Regarding Forward-Looking Information Certain information contained in this news release constitutes "forward-looking information" or "forward-looking statements" (collectively, "forward- looking information"). Without limiting the foregoing, such forward-looking information includes statements regarding the process and completion of the Offering, the use of proceeds of the Offering and any statements regarding the Company's business plans, expectations and objectives. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking information. Forward-looking information should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking information is based on information available at the time and/or the Company management's good faith belief with respect to future events and is subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. For additional information with respect to these and other factors and assumptions underlying the forward-looking information made in this news release, see the Company's most recent Management's Discussion and Analysis and financial statements and other documents filed by the Company with the Canadian securities commissions and the discussion of risk factors set out therein. Such documents are available at under the Company's profile and on the Company's website, The forward-looking information set forth herein reflects the Company's expectations as at the date of this news release and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 hours ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
